Riskpilot← Back to searchSign inGet full accessInnosurge Biologics A/S
A/SActiveCVR 38768964Alsikevej 16Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20172 employees
Revenue 2024
DKK 2,4M
+18% vs 2023
EBITDA margin
11.8%
-32% vs 2023
Equity ratio
55.0%
Financial strength
Net profit 2024
DKK 252K
-38% vs 2023
| Revenue | DKK 2,4M | +18% |
| EBITDA | DKK 289K | -32% |
| Net profit | DKK 252K | -38% |
| Total assets | DKK 3,6M | -23% |
| Equity | DKK 2M | +15% |
| Employees | 2 | — |
Legal name
Innosurge Biologics A/S
CVR number
38768964
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
23. juni 2017
Share capital
DKK 500.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et medlem af direktionen og et medlem af bestyrelsen i forening.
Company purpose
Selskabets formål er at drive virksomhed med engroshandel med læge- og hospitalsartikler og hermed forbundet virksomhed.
Address
Alsikevej 16
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -695 | 993 | 2.183 | 2.078 | 2.445 |
| Staff expenses | -2.123 | -1.587 | -1.646 | -1.652 | -2.105 |
| EBITDA | -2.818 | -594 | 538 | 426 | 289 |
| Depreciation & amort. | -0 | -0 | -5 | -5 | -5 |
| EBIT | -2.818 | -594 | 533 | 421 | 284 |
| Net financials | -68 | -22 | -43 | -14 | -32 |
| Profit before tax | -2.886 | -616 | 490 | 407 | 252 |
| Tax | -286 | -2 | -0 | -0 | -0 |
| Net profit | -2.600 | -613 | 490 | 407 | 252 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3.088 | 3.806 | 4.647 | 4.696 | 3.611 |
| Equity | 1.450 | 836 | 1.326 | 1.733 | 1.985 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.638 | 2.969 | 3.321 | 2.963 | 1.626 |
| Total debt | 1.638 | 2.969 | 3.321 | 2.963 | 1.626 |
EBITDA margin
11.8%
This company
15.8%
Market median
-25% vs market
20202024
Equity ratio
55.0%
This company
38.2%
Market median
+44% vs market
20202024
Return on equity
12.7%
This company
18.4%
Market median
+31% vs market
20202024
Net profit margin
10.3%
This company
8.1%
Market median
+27% vs market
20202024
Asset turnover
0.68×
This company
1.12×
Market median
-39% vs market
20202024
Debt / equity
0.82×
This company
0.62×
Market median
+32% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PM Chief Executive Officer | Chief Executive Officer | 2017 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Chairman | 2017 | |
| Former (1) | ||
| Board of Directors | 2017 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PMLPRO Holding ApS
Innosurge Biologics A/S Board members of Innosurge Biologics A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Møller Lassen | Chief Executive Officer | 0 companies |
| Heinz Kvottrup Lorentzen | Board of Directors | 0 companies |
| Svend Aage Jensen | Board of Directors | 0 companies |
| Michael Maigaard Nielsen | Chairman | 0 companies |